Formulation Development
SPECIAL FEATURE – Prefilled Syringes & Parenteral Manufacturing: Innovations, Challenges & Solutions
Contributor Cindy H. Dubin features several leading companies’ innovations in delivery devices as well as how contract parenteral manufacturers are addressing the ever-demanding challenges, issues, and opportunities related to delivering biologics and small molecules.
DRUG DISCOVERY – Disrupting Drug Discovery From Assay Development to Lead Compound
Zack Gurard-Levin, PhD, says with new innovations in assay methodologies, scientists no longer have to make sacrifices to do quality drug discovery research.
ANALYTICAL SERVICES – Applying Innovative Thinking & Techniques to Reduce Time-to-Market
Ramesh Jagadeesan, PhD, says that while CDMOs have the capacity to support pharmaceutical companies with their analytical requirements for both small and large-scale projects, the opportunity exists to increase speed to market with innovative thinking.
LYOPHILIZATION – Process Monitoring During Freeze-Drying
Gregory A. Sacha, PhD, describes the devices used for process monitoring and how they can be used to detect end points during the process.
FORMULATION FORUM – Application of Nano-Emulsion Technology to Address Unmet Medical Needs: A Case Study of Clopidogrel IV by 505(b)(2) Pathway
Jim Huang, PhD, presents a case study on how the EmulSol technology produces stable, optically clear nano-emulsions without the use of organic solvents and with minimal use of surfactants using a high-pressure or microfluidic homogenization process.
EXECUTIVE INTERVIEW – FSD Pharma Inc.: Is Ultra Micro-PEA the Best Untold Story in Pharma?
Raza Bokhari, MD, CEO of FSD Pharma, discusses how acquiring Prismic will benefit FSD, what makes the ultra-micronized platform unique, and how ultramicro-PEA could be the answer to ending the opioid epidemic.
GLOBAL REPORT – 2019 Global Drug Delivery & Formulation Report: Part 3, Notable Drug Delivery & Formulation Transactions & Technologies of 2019
In part 3 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on several notable drug delivery and formulation transactions and technologies.
SPECIAL FEATURE – Excipients: Matching Ingredients to Molecules Improves Functionality
Contributor Cindy Dubin speaks with several leading excipient manufacturers on how their excipient offerings are improving drug release, solubility, taste, physical characteristics, viscosity, and more for a range of molecules.
FORMULATION FORUM – Rational Design & Development of Lipid-Filled Hard Capsules
Jim Huang, PhD, says with ever increasing percentage of water-insoluble or low permeable new therapeutic entities among drug pipelines, lipid-based delivery systems, together with other main delivery technologies, have become an important tool for the development of those compounds.
THERAPEUTIC PEPTIDES – Continuous Manufacturing of Peptides Could Speed Up Development, Reduce Costs & Improve Quality
Jens Bukrinski, PhD, MSc, says the high-quality, high-process consistency between manufacturing runs and the in-line PAT analytics of the μLOT platform will enable unprecedented robustness of the manufacturing process, significantly retiring the risk of failure to supply due to non-scalability of the manufacturing process.
EXCLUSIVE ONLINE CONTENT
WEBINAR ALERT- From Diluent to Differentiator: How to Choose a Diluent System That Differentiates Your Lyophilized Product
Along with a rapidly expanding global market for innovative lyophilized biologics come increased cost and competitive pressures. Today, it is critical that….
Wondering if Investing in a Higher Purity Excipient is Really Going to Pay Off?
Wondering if investing in a higher purity excipient is really going to pay off? Check out our video web series where we speak to 3 subject matter experts on the benefits of…..
Apollomics Announces Initiation of SPARTA Phase 2 Clinical Trial
Apollomics, Inc. recent announced the initiation of the Phase 2 portion of the Phase 1/2 clinical trial for APL-101 based on completion of the Phase 1 and approval from the….
FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients
The US FDA has recently approved the investigational new drug (IND) application submitted by Octapharma USA for a Phase 3 clinical trial on…
SeraNovo Enters Second License Agreement With Carna Biosciences
SeraNovo B.V. recently announced it has signed a second License Agreement with Carna Biosciences, Inc., a company engaged in the drug development of….